Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis.

Author(s): Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P

Affiliation(s): Clinical Pharmacology Department, La Pitie Salpetriere Hospital, Assistance Publique-Hopitaux de Paris, 47 Boulevard de l'Hopital, 75013 Paris, France.

Publication date & source: 2007-02-08, Eur Heart J., [Epub ahead of print]

Publication type:

Aims Atrial fibrillation (AF) is an important morbidity-mortality risk factor, especially in patients with heart failure (HF). Beta-blockers reduce morbidity and mortality in HF. The study was designed to estimate the preventive efficacy of beta-blocker treatment on AF occurrence in patients with HF. Methods and results A systematic review of the literature was performed to identify all clinical trials evaluating beta-blockers' efficacy in HF. Eligible studies had to be randomized, placebo-controlled and providing information on the incidence of AF during follow-up among those with sinus rhythm at baseline. A total of seven studies which included 11 952 patients receiving a background treatment with angiotensin-converting enzyme-inhibitors could be found. Overall, beta-blockers significantly reduced incidence of onset of AF from 39 to 28 per 1000 patient-years: relative risk reduction = 27% (95% confidence interval 14-38, P < 0.001); heterogeneity test: P = 0.096. A same trend of efficacy was observed in all trials except the SENIORS study. In this trial which included aged patients (> 70 years) with systolic or diastolic HF, a higher prevalence of AF at baseline (35%) was observed compared with the mean baseline prevalence (13%). Conclusion Beta-blockers appear to effectively prevent occurrence of AF in patients with systolic HF.